Predicting non-response to ketamine for depression: a symptom-level analysis of real-world data
Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra, Dhakshin Ramanathan
medRxiv Preprint Server July 3, 2023 preprint DOI: 10.1101/2023.07.03.23292094 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Population | Patients with treatment resistant depression |
| Intervention | Ketamine |
| Topics | Depression Esketamine Ketamine |
| Keywords | Ketamine for depression Antidepressant ketamine Individualized treatment Tailored therapy Personalized care Symptom predictors Prognostic indicators Clinical predictors Mental health care Psychiatric care |
| Key findings | Reliable methods for predicting which patients with treatment resistant depression will respond to ketamine are lacking. |
Abstract
Background Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking.
Comparable studies
Other narrative reviews on ketamine for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine: a paradigm shift for depression research and treatment | 2019 | Review | |
| Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective | 2019 | Review | |
| Ketamine: A tale of two enantiomers | 2020 | Review | |
| Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor | 2021 | Review |